FELIX JOSE ALVAREZ RAMIRES
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
conferenceObject Brain natriuretic peptide predicts mortality in patients undergoing pericardiectomy for constrictive pericarditis(2014) MELO, D. T. P.; FERNANDES, F.; GUALANDRO, D. M.; SALEMI, V. M. C.; OLIVETTI, N. Q. S.; BUCK, P. C.; DIAS, R. R.; RAMIRES, F. J. A.; CARAMELLI, B.; MADY, C.conferenceObject Myocardial Stiffness evaluation by shear wave elastography in transthyretin amyloidosis with and without cardiac involvement(2023) ALENCAR NETO, A. C. Comte de; CAFEZEIRO, C. R. F. C. Caio Reboucas Fonseca; BUENO, B. V. K. B. Bruno Vaz Kerges; RISSATO, J. H. R. Joao Henrique; HOTTA, V. T. H. Viviane Tiemi; ALENCAR FILHO, A. C. A. F. Aristoteles Comte De; PEREIRA, F. L. P. Fernando Linhares; COUCEIRO, K. C. Katia; ROCHITTE, C. E. R. Carlos Eduardo; BARBOSA, J. M. B. B. Joao Marcos Bemfica; SOARES JUNIOR, J. S. J. Jose; RAMIRES, F. J. A. R. Felix Jose Alvarez; KALIL FILHO, R. K. F. Roberto; MATHIAS JUNIOR, W. M. J. Wilson; FERNANDES, F. F. FabioconferenceObject Coronary flow reserve by PET 13N-ammonia in patients with hereditary transthyretin amyloidosis with and without cardiac involvement(2022) ALENCAR NETO, A. C.; CAFEZEIRO, C. R. F.; BUENO, B. V. K.; SOUZA, F. Ribeiro De; RISSATO, J. H. S. Henrique; BORGES, T. Souza; CARVALHAL, S. Freitas; LIMA, M. Santos; BUCHPIGUEL, C. Alberto; CHALELA, W. Azem; RAMIRES, F. J. Alvarez; SZOR, R. Shcolnik; KALIL FILHO, R.; ROCHITTE, C. E.; FERNANDES, F.conferenceObject Galectin-3 levels are normal in patients with constrictive pericarditis and are associated with exercise intolerance after pericardiectomy(2018) FERNANDES, F.; MELLO, D. T. P.; RAMIRES, F. J. A.; SABINO, E. C.; MOREIRA, C. H. V.; BENVENUTTI, L.; HOTTA, V. T.; SAYEG, A.; DIAS, R. R.; MADY, C.conferenceObject Impairment of parasympathetic and sympathetic nervous systems in different forms of Chagas disease(2013) FERNANDES, F.; BARBOSA-FERREIRA, J. M.; RAMIRES, F. J. A.; GRUPI, C. J.; HACHUL, D. T.; IANNI, B. M.; DABARIAN, A.; NASTARI, L.; BUCK, P. C.; MADY, C.conferenceObject Non-invasive assessment of myocardial stiffness by the two-dimensional shear wave elastography ultrasound technique in patients with amyloidosis and Fabry disease(2023) CAFEZEIRO, C.; NETO, A. C. Alencar; BUENO, B. V. K.; RISSATO, J. H.; PEREIRA, N. M.; PEREIRA, F. L.; RAMIRES, F. J. A.; MATHIAS JR., W.; ROCHITTE, C. E.; HOTTA, V. T.; DABARIAN, A. L.; FERNANDES, F.conferenceObject Routine screening practices for cardiac involvement in patients with sarcoidosis(2019) MOURA, D. M. M.; ARIMURA, F. E. A.; KAIRALLA, R. A. K.; ROCHITTE, C. E. R.; DABARIAN, A. D.; FEITOSA, M. F.; CAFEZEIRO, C. R. F. C.; SOARES, J. S.; RAMIRES, F. J. A. R.; HOTTA, V. T. H.; MADY, C. M.; FERNANDES, F. F.- A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure(2015) MCMURRAY, John; PACKER, Milton; DESAI, Akshay; GONG, Jianjian; GREENLAW, Nicola; LEFKOWITZ, Martin; RIZKALA, Adel; SHI, Victor; ROULEAU, Jean; SOLOMON, Scott; SWEDBERG, Karl; ZILE, Michael R.; ANDERSEN, Karl; ARANGO, Juan Luis; ARNOLD, Malcolm; BELOHLAVEK, Jan; BOEHM, Michael; BOYTSOV, Sergey; BURGESS, Lesley; CABRERA, Walter; CHEN, Chen-Huan; ERGLIS, Andrejs; FU, Michael; GOMEZ, Efrain; GONZALEZ, Angel; HAGEGE, Albert-Alain; KATOVA, Tzvetana; KIATCHOOSAKUN, Songsak; KIM, Kee-Sik; BAYRAM, Edmundo; MARTINEZ, Felipe; MERKELY, Bela; MENDOZA, Ivan; MOSTERD, Arend; NEGRUSZ-KAWECKA, Marta; PEUHKURINEN, Keijo; RAMIRES, Felix; REFSGAARD, Jens; SENNI, Michele; SIBULO JR., Antonio S.; SILVA-CARDOSO, Jose; SQUIRE, Iain; STARLING, Randall C.; VINEREANU, Dragos; TEERLINK, John R.; WONG, RaymondAims Although active-controlled trials with reninangiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos. Methods and results We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-Alternative trial (CHARM-Alternative) as the reference trial for comparison of an ARB to placebo. The hazard ratio of LCZ696 vs. a putative placebo was estimated through the product of the hazard ratio of LCZ696 vs. enalapril (active-control) and that of the historical active-control (enalapril or candesartan) vs. placebo. For the primary composite outcome of cardiovascular death or heart failure hospitalization in PARADIGM-HF, the relative risk reduction with LCZ696 vs. a putative placebo from SOLVD-T was 43% (95%CI 3450%; P < 0.0001) with similarly large effects on cardiovascular death (34%, 2144%; P < 0.0001) and heart failure hospitalization (49%, 3958%; P < 0.0001). For all-cause mortality, the reduction compared with a putative placebo was 28% (95%CI 1539%; P < 0.0001). Putative placebo analyses based on CHARM-Alternative gave relative risk reductions of 39% (95%CI 2748%; P < 0.0001) for the composite outcome of cardiovascular death or heart failure hospitalization, 32% (95%CI 1645%; P < 0.0001) for cardiovascular death, 46% (3356%; P < 0.0001) for heart failure hospitalization, and 26% (95%CI 1139%; P < 0.0001) for all-cause mortality. Conclusion These indirect comparisons of LCZ696 with a putative placebo show that the strategy of combined angiotensin receptor blockade and neprilysin inhibition led to striking reductions in cardiovascular and all-cause mortality, as well as heart failure hospitalization. These benefits were obtained even though LCZ696 was added to comprehensive background beta-blocker and mineralocorticoid receptor antagonist therapy.
conferenceObject Effects of exercise training on cardiovascular autonomic modulation and skeletal muscle tissue in chagasic cardiopathy patients and preserved systolic function(2018) SARMENTO, A. S. O.; ANTUNES-CORREA, L. M.; ALVES, M. J. N. N.; BACURAU, A. V. N.; FONSECA, K. C. B.; PESSOA, F. G.; TROMBETTA, I. C.; RONDON, M. U. P. B.; RAMIRES, F. J. A.; BRASILEIRO-SANTOS, M. S.; BRUM, P. C.; MADY, C.; NEGRAO, C. E.; THOMAS, S.; IANNI, B. M.conferenceObject Dysregulation of insulin levels in Chagas heart disease is associated with altered adipocytokine levels(2018) DABARIAN, A.; MADY, C.; FERREIRA, J. M. B.; IANNI, B.; HOTTA, V. T.; RAMIRES, F. J. A.; LOPES, H. F.; FERNANDES, F.